Diagnosis and treatment of multicentric occurring hepatocellular carcinoma using molecular biological technique

分子生物学技术对多中心性肝细胞癌的诊治

• 批准号: 11671263
• 负责人: SHIMADA Hiroshi
• 金额: $ 2.11万
• 依托单位: Yokohama City University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1999
• 资助国家: 日本
• 起止时间: 1999 至 2001
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-11671263/
• 关键词: hepatocellular carcinoma; multicentricity; intrahepatic metastasis; survival rate; HBV-DNA integration pattern; nm23-H1 gene; p53 gene; nm23-H1遺伝子; TAI; p^<53>遺伝子

<Purpose>The aim of this study was to differentiate metachronously multicentric occurring hepatocellular carcinoma (MC) from intrahepatic metastatic HCC (IM) and to clarify clinical characteristics of them.<Materials and methods>Among 110 HCC patients with solitary nodules in the diameter of less than 5 cm having no capsular invasion and portal thrombus, 45 had recurrence. Recurrent HCC of twenty-nine patients were studied. Histological criteria and molecular biological criteria using HBV-DNA integration pattern, p53 mutation pattern and nm23-H1 expression were applied to define the multicentricity.<Results>1. MC was defined in 14 patients (61 %), IM in 9 (39 %) and unclassified cases was in 6. Among 23 patients 16 was defined histologically and 7 was molecular biologically.2. Solitary recurrence were found in 1 of 9 (11 %) IM patients and 11 of 14 (80 %) MC patients, respectively (p < 0.05), well-differentiated HCC were found in 0 of 9 (0 %) and 8 of 14 (57 %), respectively (p < 0.05). Interval time between the hepatectomy and recurrence were 13.5 months in IM and 26.7 months in MC, respectively (p < 0.05).<Conclusion>1. MC was defined in 14 patients (61 %) and IM in 9 (39 %).2. From the clinical viewpoint solitary well-differentiated HCC which was detected 2 years after the hepatectomy might be MC.

<Purpose>本研究的目的是鉴别异时多中心发生的肝细胞癌（MC）和肝内转移性肝癌（IM），并阐明它们的临床特征。<Materials and methods>110例直径小于5cm、无包膜侵犯、无门静脉血栓的原发性肝癌患者中，45例复发。对29例复发性HCC患者进行了研究。采用组织学标准和分子生物学标准，以HBV-DNA整合模式、p53突变模式和nm 23-H1表达来定义多中心性。<Results>1. 14例患者（61%）确诊为MC，9例（39%）确诊为IM，6例未分类病例。23例中16例为组织学确诊，7例为分子生物学确诊. IM组和MC组分别有1/9（11%）和11/14（80%）复发（p &lt; 0.05），高分化肝癌分别为0/9（0%）和8/14（57%）（p &lt; 0.05）。肝切除术后至复发的间隔时间IM组为13.5个月，MC组为26.7个月（P &lt; 0.05）。<Conclusion>1. MC 14例（61%），IM 9例（39%）.从临床角度来看，肝切除术后2年发现的孤立性高分化HCC可能是MC。

项目成果

長堀 薫: "術中右肝動脈損傷時の対処"日本臨床外科学会雑誌. (in press). (2000)

Kaoru Nagahori：“手术期间右肝动脉受伤时的应对”，日本临床外科学会杂志（2000 年出版）。

長堀 薫: "肝細胞癌と鑑別が困難であった肝細胞腺腫の1例"肝臓. 42(6). 321-326 (2001)

Kaoru Nagahori：“一例难以与肝细胞癌鉴别的肝细胞腺瘤” 肝脏 42(6) (2001)。

Y Nagano: "Laparoscopic surgery for pedunculated focal nodular hyperplasia, report of a case"Endoscopy. 31(Suppl1). 24-25 (1999)

Y Nagano：“腹腔镜手术治疗带蒂局灶性结节性增生，一例报告”内窥镜检查。

Hitoshi Sekido: "Liver transplantation for primary sclerosing cholangitis"J Hepatobiliary Pancreat Surg. 6. 373-376 (1999)

Hitoshi Sekido：“原发性硬化性胆管炎的肝移植”J Hepatobiliary Pancreat Surg。

Nagano Y: "Improved functional reserve of hypertrophied contra lateral liver after portal vein ligation"Journal of Hepatology. (in press). (2002)

Nagano Y：“门静脉结扎后肥大的对侧肝脏的功能储备得到改善”肝脏病学杂志。